17 completed, 5 terminated, 5 unknown. 27 Phase 2, 8 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 17, Terminated 5, Unknown 5 |
| Phase 3 | 8 | Completed 6, Unknown 2 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
Follow Panic Disorder: new trials by email Literature Review of Panic Disorder trials Research Report on Panic Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder Darigabat, Placebo - Panic Disorder | Phase 2 | Terminated | AbbVie | 80 | 2023-07-31 | 2026-05-07 |
| Safety and Efficacy of HB-1 for Panic Disorder HB-01, Placebo - Panic Disorder | Phase 2 | Completed | HB BioTech, LLC | 86 | 2022-02-03 | 2025-03-18 |
| Xenon Inhalation for Treatment of Panic Disorder Xenon, Placebo - Panic Disorder | Phase 2 / Phase 3 | Unknown | Nobilis Therapeutics Inc. | 200 | 2021-06-01 | 2021-03-03 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
| Disruption of Memory Reconsolidating as a Treatment for Panic Disorder Propranolol, Placebo, Carbon dioxide - Panic Disorder | Phase 2 | Unknown | VU University of Amsterdam | 60 | 2016-04-01 | 2015-12-16 |
| Different Neural Circuit Mechanisms Between Cognitive Therapy and Behavior Therapy for Patients With Panic Disorder: a Dynamic Research Cognitive therapy, Behavior therapy, SSRI antidepressants - Panic Disorder | Phase 2 | Unknown | Nanjing Medical University | 96 | 2016-01-01 | 2017-06-27 |
| Bringing What Works to Youth in Corrections: A Trauma Intervention Trauma-Focused Cognitive Behavioral Therapy - Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 57 | 2012-11-01 | 2016-03-17 |
| Online Treatments for Mood and Anxiety Disorders in Primary Care CCBT+ISG/Collaborative Care, CCBT/Collaborative Care - Depression, Generalized Anxiety Disorder | Phase 2 / Phase 3 | Completed | University of Pittsburgh | 700 | 2012-02-01 | 2020-08-05 |
| Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia CBT, D-Cycloserine - Agoraphobia | Phase 2 | Completed | Charite University, Berlin, Germany | 73 | 2011-11-01 | 2014-05-19 |
| Mechanisms of Panic Disorders Treatment Cognitive Behavioural Therapy (CBT) - Panic Disorder, Agoraphobia | Phase 2 / Phase 3 | Unknown | University Medicine Greifswald | 180 | 2010-03-01 | 2011-04-11 |
| Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) Cognitive-behavioral therapy, Org 25935, Placebo - Panic Disorder | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 46 | 2008-07-23 | 2018-10-16 |
| Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder d-cycloserine, placebo - Panic Disorder | Phase 2 | Completed | Boston University Charles River Campus | 180 | 2008-04-01 | 2018-03-07 |
| Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS) - Panic Disorder, Major Depressive Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 25 | 2007-10-01 | 2014-09-22 |
| Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Personality-targeted interventions - Alcohol Abuse, Drug Abuse | Phase 2 / Phase 3 | Completed | King's College London | 3190 | 2007-05-01 | 2011-06-27 |
| Staccato Alprazolam in Panic Attack Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg - Treatment of Induced Panic Attack | Phase 2 | Completed | Alexza Pharmaceuticals, Inc. | 49 | 2007-05-01 | 2017-06-16 |
| Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Physical exercise, Cognitive-behavioral therapy - Panic Disorder | Phase 2 | Completed | University of Bergen | 36 | 2007-05-01 | 2010-02-26 |
| ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment ELB139 - Panic Disorder | Phase 2 | Terminated | elbion AG | 24 | 2006-05-01 | 2006-09-29 |
| Levetiracetam for the Treatment of Alcohol Dependence and Anxiety levetiracetam - Alcoholism, Generalized Anxiety Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 3 | 2004-03-01 | 2019-04-24 |
Showing 20 of 27. Sign in to see all of them.
Anxiety Disorders (9) · Depression (5) · Generalized Anxiety Disorder (5) · Agoraphobia (3) · Alcoholism (3) · Depressive Disorder, Major (3) · Mental Disorders (3) · Phobia, Social (3) · Stress Disorders, Post-Traumatic (3) · Conduct Disorder (2) · Substance-Related Disorders (2) · Ageusia (1) · Anosmia (1) · Antisocial Personality Disorder (1)
Mental Disorders (24) · Anxiety Disorders (18) · Behavior (6) · Behavioral Symptoms (5) · Phobic Disorders (5) · Mood Disorders (4) · Alcohol-Related Disorders (3) · Chemically-Induced Disorders (3) · Depressive Disorder (3) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Attention Deficit and Disruptive Behavior Disorders (2) · Disease Attributes (2) · Nervous System Diseases (2) · Neurodevelopmental Disorders (2)
Cognitive Behavioral Therapy (5) · Behavior Therapy (2) · Cycloserine (2) · 1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-one (1) · Alprazolam (1) · Bulk Drugs (1) · Carbon Dioxide (1) · Clonazepam (1) · Commerce (1) · Compressed Air (1) · Dosage Forms (1) · Doxapram (1) · Exercise (1) · Interpersonal Psychotherapy (1) · Levetiracetam (1)
University of Pittsburgh (3) · HB BioTech, LLC (2) · King's College London (2) · New York State Psychiatric Institute (2) · AbbVie (1) · Alexza Pharmaceuticals, Inc. (1) · All Natural Medicine Clinic, LLC (1) · Beth Israel Medical Center (1) · Boston University Charles River Campus (1) · Charite University, Berlin, Germany (1) · Massachusetts General Hospital (1) · Medical Research Council Cognition and Brain Sciences Unit (1) · Merck Sharp & Dohme LLC (1) · Nanjing Medical University (1) · National Institute on Drug Abuse (NIDA) (1)
United States (15) · Germany (3) · United Kingdom (3) · Australia (1) · China (1) · Netherlands (1) · Norway (1)
Bruce L. Rollman, MD, MPH (2) · Alexander L. Gerlach, Prof. Dr. (1) · Alfons O. Hamm, Prof. Dr. (1) · Anders Hovland, PsyD (1) · Antonio Mantovani, MD (1) · Barbara Milrod, M.D. (1) · Chun Wang, doctor (1) · David F Tolin, PhD (1) · David Walling (1) · Eric Griez, Prof Dr (1) · Frances R Levin, MD (1) · Georg W. Alpers, Prof. Dr. (1) · Igor Galynker, MD, PhD (1)
PMID 20732631, PMID 10197825, PMID 12113998, PMID 12217271, PMID 14557145, PMID 15580167, PMID 15982444, PMID 16330721, PMID 17215046, PMID 17592913, PMID 18373143, PMID 19026262, PMID 19814948, PMID 20048226, PMID 20869813, PMID 22394471, PMID 22858212, PMID 23344135, PMID 26011508, PMID 26877119, PMID 26881449, PMID 27235836, PMID 27315514, PMID 30082367, PMID 30341278, PMID 30718541, PMID 30865304, PMID 31712720, PMID 31734525, PMID 31838872, PMID 32734299, PMID 32880104, PMID 34267085, PMID 38231552, PMID 9448663, PMID 9821564
K23MH001831 (1), K23MH001849 (1), R01MH059395 (1), R01MH081116 (1), R34MH095210 (1)